Nachrichten zur Johnson Matthey PLC Aktie

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Johnson & Johnson also reported a fourth-quarter profit ahead of expectations, buoyed by strong sales of the blood cancer therapy…

Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts

Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026…

U.S. judge allows experts to testify that talc products cause cancer in J&J cases

In a victory for thousands of women suing Johnson & Johnson over claims that the companys baby powder and…

Robotic surgery fuels Johnson & Johnson dividend growth outlook

Johnson & Johnson (JNJ) just made a move that investors have been waiting years to see. The healthcare heavyweight submitted…

Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson

Netflix, Intel and Johnson & Johnson headline Zacks Investment Ideas as key earnings reports approach amid steady estimates.…

Major Earnings Reports Streaming In: Global Week Ahead

The fourth-quarter U.S. earnings season heats up, with reports due from high-profile companies including Netflix (NFLX), Johnson & Johnson (JNJ),…

Tech Still Matters. But It’s a Good Thing More Stocks Are Rallying.

Stocks beyond tech are getting their day in the sun. Stocks like Morgan Stanley, Johnson & Johnson, and Caterpillar are…

Johnson & Johnson (JNJ) Beats Stock Market Upswing: What Investors Need to Know

Johnson & Johnson (JNJ) closed the most recent trading day at $209.72, moving +2.61% from the previous trading session.…

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Johnson & Johnson Aktie: Comeback für Healthcare 2026?

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Sanford C. Bernstein:Bernstein-Analyst Lee Hambright habe das Kursziel für die Aktie von…

Johnson & Johnson reaches deal with US government to lower drug prices

Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trumps administration to cut drug…

Top Analyst Reports for Johnson & Johnson, Caterpillar and Qualcomm

JNJ is leaning on Innovative Medicine growth and MedTech momentum to offset the Stelara patent cliff as it heads into…

Covid-19: Bayer verklagt Biontech und Pfizer wegen Patenten für Impfstoffe

Der Pharmakonzern Bayer wirft Pfizer, Biontech und Moderna vor, bei ihren Covid-19-Impfstoffen eine patentierte mRNA-Technologie der Bayer-Tochter Monsanto genutzt zu…

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from…

Johnson & Johnson Aktie: Diese Medikamente könnten jetzt für den nächsten Schub sorgen!

London (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Barclays:Barclays habe das Kursziel für die Aktie von Johnson & Johnson (J&J) (ISIN:…

Apogee Therapeutics Aktie: J&J-Flop öffnet Tür für APG279

New York (www.aktiencheck.de) - Apogee Therapeutics-Aktienanalyse von BTIG:Die Analysten von BTIG haben das "buy"-Rating für die Aktie von Apogee Therapeutics…

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Johnson & ?Johnson said ?it ?discontinued ?a ?mid-stage study of its experimental drug ?to treat atopic dermatitis, after it ?failed…

The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley

Invesco leads Zack list of five high-yield S&P 500 stocks, highlighting dividend strength and steady income potential for 2026.…

Johnson & Johnson pledges appeal following record $1.5 billion U.S. jury verdict in talc cancer case

…

Johnson & Johnson Aktie: RBC hebt Kursziel auf 240 USD - Wachstumschancen 2026!

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets:Die Analysten von RBC Capital Markets haben das Kursziel für die…

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

…

Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?

Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to ones portfolio. Wall Street analysts…

Johnson & Johnson Aktie: MedTech auf Wachstumskurs trotz Stelara-LOE - RBC hebt Kursziel an

Toronto (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von RBC Capital Markets:Die Analysten vom Investmenthaus RBC Capital Markets stufen die Aktie von…

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial By Reuters

Jury orders Johnson & Johnson to pay $40 million to two women in latest talc trial…

These Institutional Investors Are Raising Their Stakes in Johnson & Johnson Stock. Should You Do the Same?

They might be on to something.…

Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous…

Johnson & Johnson Aktie: Medtech gilt als heimlicher Underperformer mit Turbo-Potenzial!

New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse der Citigroup:Citi-Analystin Joanne Wuensch habe das Kursziel für die Aktie von Johnson &…

The Zacks Analyst Blog Highlights Broadcom, Exxon Mobil, Johnson & Johnson, Investors Title and Friedman Industries

AVGO draws attention as analysts spotlight its AI-driven momentum alongside notable updates on XOM, JNJ, ITIC and FRD.…

GSK Underweight

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK nach detaillierten Studiendaten von Johnson & Johnson…

Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note

The latest trading day saw Johnson & Johnson (JNJ) settling at $202.48, representing a -1.39% change from its previous close.…

AKTIONÄR-Top-Tipp Merck & Co: Hoffnung im Kampf gegen Alzheimer

Trotz derzeit zwei zugelassener Alzheimer-Medikamente in den USA respektive Europa ist der medizinische Bedarf immer noch extrem hoch. Zuletzt sind…

Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Pharma Deutschland erweitert Vorstand auf Mitgliederversammlung 2025 / Mitgliederversammlung wählt Hatice Camdere (Amgen GmbH), Susanne Lamminger (HexalAG/Sandoz) und Christian Thams (Johnson&Johnson)

Pharma Deutschland e.V.: Berlin (ots) - Auf der 71. Mitgliedersammlung von Pharma Deutschland wurden drei neue Vorstandsmitglieder berufen. Die neuen…

Alphabet klettert entgegen dem Markttrend nach oben - Johnson & Johnson übernimmt Halda Therapeutics

Wien (www.aktiencheck.de) - Im Fokus stand gestern Alphabet (ISIN: US02079K3059, WKN: A14Y6F, Ticker-Symbol: ABEA, NASDAQ-Symbol: GOOGL): Die Google-Mutter kletterte entgegen…

Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisition

Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology…

Why Is Johnson & Johnson (JNJ) Up 1.7% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…

Johnson & Johnson: Doppelschlag - milliardenschwere Übernahme zahlt sich aus

Der US-Konzern verzeichnet weitere wichtige Fortschritte in seiner Biopharma-Sparte. Am gestrigen Donnerstag konnte Johnson & Johnson gleich zwei Marktzulassungen vonseiten…

Heres Why Johnson & Johnson (JNJ) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

IRW-News: ACCESS Newswire: Führende Fortune-500-Unternehmen berichten im Rahmen einer OMP-Konferenz über KI-Kompetenzen zur Stärkung der Lieferkette

IRW-PRESS: ACCESS Newswire: Führende Fortune-500-Unternehmen berichten im Rahmen einer OMP-Konferenz über KI-Kompetenzen zur Stärkung der LieferketteBranchenriesen wie AstraZeneca, Johnson &…

This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy @themotleyfool #stocks $JNJ $^GSPC

Johnson & Johnson has a very healthy financial profile and growth prospects.…

dpa-AFX ProFeed